{"id":389137,"date":"2023-11-16T00:00:00","date_gmt":"2023-11-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2023-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2023\/"},"modified":"2026-05-01T11:24:30","modified_gmt":"2026-05-01T11:24:30","slug":"dlsfon0017-2023-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2023-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Hepatocellular Carcinoma | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>The hepatocellular carcinoma therapy market is gradually evolving and experiencing substantial growth. While angiogenesis inhibitors, including sorafenib (Bayer \/ Amgen), Stivarga (Bayer), Lenvima (Eisai \/ Merck &#038; Co.), Cabometyx (Exelixis \/ Ipsen \/ Takeda), and Cyramza (Eli Lilly), have been central to the treatment of advanced disease, the market is expected to undergo a significant shift over the next 10 years. This shift will be driven by the approvals of Tecentriq (Roche \/ Genentech) plus bevacizumab and of Imfinzi plus Imjudo (AstraZeneca \/ MedImmune); the FDA\u2019s accelerated approval of Opdivo plus Yervoy (Bristol Myers Squibb \/ Ono Pharmaceutical); and the anticipated entry of novel immune checkpoint inhibitor-based combinations. The expected uptake of these premium-priced regimens and their label expansion to the untapped early-stage setting will drive robust growth of the hepatocellular carcinoma therapy market, in which unmet needs remain to offer further opportunities for growth.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the size of the market-relevant drug-treatable populations, and how will drug-treatment rates change over time?<\/li>\n<li>What are the current therapies for hepatocellular carcinoma, and what are the main unmet needs?<\/li>\n<li>What is the expected market impact of recent and forecast drug approvals on the various subpopulations of hepatocellular carcinoma? What are interviewed experts\u2019 insights on key existing and emerging therapies?<\/li>\n<li>What are the key factors driving or constraining market growth?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389137","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatocellular-carcinoma","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389137\/revisions"}],"predecessor-version":[{"id":576046,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389137\/revisions\/576046"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}